Fulvestrant is a pure anti-estrogen hormoal agent formally lacking any estrogen-agonist activity. We analyze the effect(s) of fulvestrant treatment on estrogen target systems in hormoe-sensitive advanced breast cancer patients. Patients received a median of five fulvestrant injections (range 3-19). We observed a partial response in one patient, disease stability in 21 and disease progression in 29 patients with a clinical benefit of 43.2% and a median time to progression of 5 [range 3-20] mo. Total cholesterol levels significantly decreased during treatment (219.8 +/- 45.3 vs. 201.4 +/- 42.1 mg/dl; p = 0.0054) together with LDL-cholesterol (129.7 +/- 41.39 vs. 112.3 +/- 37.1 mg/dl; p = 0.018). HDL-cholesterol and triglycerides did not show significant changes. Reduction of total and LDL-cholesterol was independent from last hormoal treatment or treatment duration. All coagulation indices and mean endometrial mucosa thickness value did not vary. Fifty-one patients [median age 65 (range 48-82) y] were enrolled. All patients received previous hormoal treatments, with 90.2% receiving > or =2 courses. Last hormoal treatment was exemestane, letrozole, anastrozole and other in 30-10-7-4/51 patients respectively. Median withdrawal time was 18 d (range 3-1456). Complete fasting lipid blood profile and coagulation indices were assessed before fulvestrant administration, every 3 mo and at discontinuation time. Endometrial mucosa thickness was evaluated before fulvestrant administration and at end-study time. We observed a lipid lowering effect of fulvestrant possibly related to an influence on lipid metabolism by a mechanism in which a role could be played by progesterone receptor.

Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone receptor-positive metastatic breast cancer patients / Andrea, Camerini; Marianna, Rondini; Ornella, Garrone; Chiara, Valsuani; Sara, Donati; Olimpia, Siclari; Alessandro, Sgambato; Gianna, Tartarelli; Maura, Vincenti; V. P., Mattiot; PROSPERI PORTA, Romana; Cheti, Puccetti; Paolo, Puccinelli; Domenico, Amoroso. - In: CANCER BIOLOGY & THERAPY. - ISSN 1538-4047. - STAMPA. - 8:15(2009), pp. 1450-1455. [10.4161/cbt.8.15.8959]

Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone receptor-positive metastatic breast cancer patients

PROSPERI PORTA, Romana;
2009

Abstract

Fulvestrant is a pure anti-estrogen hormoal agent formally lacking any estrogen-agonist activity. We analyze the effect(s) of fulvestrant treatment on estrogen target systems in hormoe-sensitive advanced breast cancer patients. Patients received a median of five fulvestrant injections (range 3-19). We observed a partial response in one patient, disease stability in 21 and disease progression in 29 patients with a clinical benefit of 43.2% and a median time to progression of 5 [range 3-20] mo. Total cholesterol levels significantly decreased during treatment (219.8 +/- 45.3 vs. 201.4 +/- 42.1 mg/dl; p = 0.0054) together with LDL-cholesterol (129.7 +/- 41.39 vs. 112.3 +/- 37.1 mg/dl; p = 0.018). HDL-cholesterol and triglycerides did not show significant changes. Reduction of total and LDL-cholesterol was independent from last hormoal treatment or treatment duration. All coagulation indices and mean endometrial mucosa thickness value did not vary. Fifty-one patients [median age 65 (range 48-82) y] were enrolled. All patients received previous hormoal treatments, with 90.2% receiving > or =2 courses. Last hormoal treatment was exemestane, letrozole, anastrozole and other in 30-10-7-4/51 patients respectively. Median withdrawal time was 18 d (range 3-1456). Complete fasting lipid blood profile and coagulation indices were assessed before fulvestrant administration, every 3 mo and at discontinuation time. Endometrial mucosa thickness was evaluated before fulvestrant administration and at end-study time. We observed a lipid lowering effect of fulvestrant possibly related to an influence on lipid metabolism by a mechanism in which a role could be played by progesterone receptor.
2009
fulvestrant; endometrial mucosa; breast cancer; hormonal treatment; lipids; estrogen; progesteron; advanced breast cancer; progesterone; cholesterol; coagulation
01 Pubblicazione su rivista::01a Articolo in rivista
Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone receptor-positive metastatic breast cancer patients / Andrea, Camerini; Marianna, Rondini; Ornella, Garrone; Chiara, Valsuani; Sara, Donati; Olimpia, Siclari; Alessandro, Sgambato; Gianna, Tartarelli; Maura, Vincenti; V. P., Mattiot; PROSPERI PORTA, Romana; Cheti, Puccetti; Paolo, Puccinelli; Domenico, Amoroso. - In: CANCER BIOLOGY & THERAPY. - ISSN 1538-4047. - STAMPA. - 8:15(2009), pp. 1450-1455. [10.4161/cbt.8.15.8959]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/125687
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 2
social impact